Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Justin Overhoff

Physician Assistant, Medical Spokane, WA Physician Assistant

NPI 1508331836 CMS profile 11023541

1401 E Trent Ave 200, Spokane, WA 99202

Open in the dashboard

General payments

$4,545

182 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Justin Overhoff of Spokane, WA is reported in the CMS Open Payments database as having received $4,545 across 182 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,326 44
2024 General $1,116 39
2023 General $709 29
2022 General $393 16
2021 General $1,001 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Justin Overhoff
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Justin Overhoff were reported at $1,326. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Justin Overhoff Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,001 $156 $41–$563 $132
2022 $393 $185 $55–$649 $149
2023 $709 $199 $58–$717 $160
2024 $1,116 $206 $62–$740 $164
2025 $1,326 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Sumitomo Pharma America, Inc. $586 22 payments
  2. Janssen Biotech, Inc. $536 22 payments
  3. AbbVie, Inc. $484 14 payments
  4. Astellas Pharma US Inc $459 13 payments
  5. Dendreon Pharmaceuticals LLC $318 11 payments
  6. Boston Scientific Corporation $297 6 payments
  7. Myriad Genetic Laboratories, Inc. $229 14 payments
  8. Accord Healthcare, Inc. $169 8 payments
  9. Ferring Pharmaceuticals Inc. $127 4 payments
  10. TOLMAR Pharmaceuticals, Inc. $119 6 payments
  11. Other $1,222 62 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,247 178 payments
  2. Education $298 4 payments
Products named General payments · program years 2021–2025
  1. GEMTESA $598 22 payments
  2. ERLEADA $487 20 payments
  3. PROVENGE $318 11 payments
  4. XTANDI $287 13 payments
  5. BOTOX Urology $225 2 payments
  6. BOTOX Botox Therapeutic $163 8 payments
  7. AMS 700 $148 3 payments
  8. ELIGARD $139 7 payments
  9. CAMCEVI $130 6 payments
  10. ADSTILADRIN $127 4 payments
  11. Other $1,870 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,433

Median for Physician Assistant: 241

Drug cost

$153,581

Median for Physician Assistant: $4,110

Branded share of claims

27.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 101 $77,692
Gemtesa Vibegron Brand 50 $32,421
Elmiron Pentosan Polysulfate Sodium Brand 14 $8,962
Methenamine Hippurate Generic 135 $7,844
Silodosin Generic 111 $6,603
Tamsulosin Hcl Generic 451 $6,333
Estradiol Generic 36 $2,845
Potassium Citrate Er Potassium Citrate Brand 33 $2,142
Solifenacin Succinate Generic 44 $1,669
Fosfomycin Tromethamine Generic 29 $1,440

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$78,308

Of which drugs: $11,456

Medicare patients

326

Average age 74

Services billed

3,591

58 women, 268 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 48%
Diabetes 32%
Cancer 30%
Chronic kidney disease 27%
Ischemic heart disease 26%
Atrial fibrillation 24%
Depression 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $185
$185 50 —
PROVENGE
  • Dendreon Pharmaceuticals LLC $174
$174 — —
BOTOX
  • AbbVie, Inc. $165
$165 — —
Trelstar
  • Verity Pharmaceuticals Inc. $109
$109 — —
ERLEADA
  • Janssen Biotech, Inc. $71
$71 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

182 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record